Rapt Therapeutics Inc Reports Results For The Quarter Ended December 31: Earnings Summary
06/03/2025 13:58
RAPT Therapeutics Inc RAPT.OQ reported a quarterly adjusted loss of $1.14 per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -80 cents. The mean expectation of five analysts for the quarter was for a loss of 37 cents per share. Wall Street expected results to range from -58 cents to -16 cents per share. Reported revenue was zero; analysts expected zero. RAPT Therapeutics Inc's reported EPS for the quarter was a loss of $1.14. The company reported a quarterly loss of $53.31 million. RAPT Therapeutics Inc shares had fallen by 28.5% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 15.7% in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold" Wall Street's median 12-month price target for RAPT Therapeutics Inc is $4.00 This summary was machine generated from LSEG data March 6 at 01:58 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.37 | -1.14 | Missed |
| Sep. 30 2024 | -0.56 | -0.47 | Beat |
| Jun. 30 2024 | -0.72 | -0.71 | Beat |
| Mar. 31 2024 | -0.81 | -0.79 | Beat |